November 30, 2016 - By Peter Erickson · 0 Comments
The stock of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) registered an increase of 18.05% in short interest. CRBP’s total short interest was 3.68M shares in November as published by FINRA. Its up 18.05% from 3.12 million shares, reported previously. With 2.36 million shares average volume, it will take short sellers 2 days to cover their CRBP’s short positions. The short interest to Corbus Pharmaceuticals Holdings’s float is 13.54%. About 37,585 shares traded hands. Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has risen 252.42% since April 27, 2016 and is uptrending. It has outperformed by 247.20% the S&P500.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The company has a market cap of $330.94 million. The Firm is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. It currently has negative earnings. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.
Out of 4 analysts covering Corbus Pharma (NASDAQ:CRBP), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Corbus Pharma has been the topic of 4 analyst reports since September 8, 2015 according to StockzIntelligence Inc. On Monday, March 7 the stock rating was initiated by Aegis Capital with “Buy”. The firm earned “Mkt Outperform” rating on Tuesday, September 8 by JMP Securities. Noble Financial maintained it with “Buy” rating and $19 target price in Friday, November 11 report. The stock has “Buy” rating given by Cantor Fitzgerald on Wednesday, October 5.
Corbus Pharmaceuticals Holdings, Inc., incorporated on December 18, 2013, is a clinical-stage pharmaceutical company. The Firm is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. The Company’s product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis (CF), systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration (the FDA) has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis.
More recent Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) news were published by: Fool.com which released: “Why Corbus Pharmaceuticals Holdings Inc. Skyrocketed Higher Today” on November 14, 2016. Also Fool.com published the news titled: “Why Corbus Pharmaceuticals Holdings Inc Jumped Higher Today” on October 19, 2016. Fool.com‘s news article titled: “Why Corbus Pharmaceuticals Holdings Inc Shares Skyrocketed Today” with publication date: October 05, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Peter Erickson